Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 4, 2011, Pages 483-489

  Gaiolla, Rafael D ^a   Domingues, Maria A C ^a   Niéro Melo, Lígia ^a   De Oliveira, Deilson Elgui ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IL10 PROTEIN, HUMAN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; INTERLEUKIN DERIVATIVE; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; CANCER STAGING; DISEASE COURSE; DRUG MONITORING; FEMALE; HODGKIN DISEASE; HUMAN; MALE; METHODOLOGY; TIME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG MONITORING; FEMALE; HODGKIN DISEASE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-6; INTERLEUKINS; MALE; NEOPLASM STAGING; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79955104289     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Straus DJ. Treatment of early-stage nonbulky Hodgkin lymphoma. Curr Opin Oncol. 2006; 18(5): 432-436. (Pubitemid 44199837)
2. Diehl V. Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's disease. J Clin Oncol. 2004; 22(1): 15-18. (Pubitemid 41095108)
3. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004; 22(1): 62-68. (Pubitemid 41095115)
4. Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999; 17(2): 534-545. (Pubitemid 29075240)
5. Bartlett NL. Therapies for relapsed Hodgkin lymphoma: transplant and nontransplant approaches including immunotherapy. Hematology Am Soc Hematol Educ Program. 2005; 245-251.
6. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol. 2008; 141(1): 3-13. (Pubitemid 351347529)
7. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993; 11(11): 2258-2272. (Pubitemid 23332265)
8. Dühmke E, Diehl V, Loeffler M, et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys. 1996; 36(2): 305-310. (Pubitemid 26359453)
9. Gospodarowicz MK, Sutcliffe SB, Bergsagel DE, Chua T; Princess Margaret Hospital Lymphoma Group. Radiation therapy in clinical stage I and II Hodgkin's disease. Eur) Cancer. 1992; 28A(11): 1841-1846.
10. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998; 339(21): 1506-1514. (Pubitemid 28543499)
11. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003; 225-247.
12. Klimm B, Diehl V, Pfistner B, Engert A. Current treatment strategies of the German Hodgkin Study Group (GHSG). Eur J Haematol Suppl. 2005; (66): 125-134. (Pubitemid 40873990)
13. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002; 99(12): 4283-4297. (Pubitemid 34627193)
14. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma. Experimental Hematology. 2006; 34(4): 399-406.
15. Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005; 231-238.
16. Gruss HJ, Pinto A, Duyster), Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today. 1997; 18(4): 156-163. (Pubitemid 27192176)
17. Schmitz R, Stanelle J, Hansmann ML, Kuppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009; 4: 151-174.
18. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. 2005; 105(12): 4553-4560. (Pubitemid 40807270)
19. Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. Leuk Lymphoma. 2000; 36(3-4): 363-371.
20. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissue. Ann Oncol. 2002; 13(suppl 1): 52-56. (Pubitemid 34567402)
21. Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood. 2004; 103(8): 3216-3221. (Pubitemid 38451701)
22. Reynolds GM, Billingham LJ, Gray LJ, et al. Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol. 2002; 118(1): 195-201. (Pubitemid 34779537)
23. Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. Serum interleukin10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica. 2001; 86(3): 274-281. (Pubitemid 32291065)
24. Skinnider BF, Kapp U, Mak TW. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma. 2002; 43(6): 1203-1210. (Pubitemid 34537964)
25. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993; 53(9): 2118-2122. (Pubitemid 23145736)
26. Seymor JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated levels of interleukin-6 in patients with untreated Hodgkin's disease. Am J Med. 1997; 102(1): 21-28. (Pubitemid 27089983)
27. Sards AH, Kliche KO, Pethambaram P, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999; 10(4): 433-440. (Pubitemid 29236421)
28. Herling M, Rassidakis GZ, Medeiros JL, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res. 2003; 9(60): 2114-2120. (Pubitemid 36687633)
29. Herbst H, Foss HD, Samoi I, et al. Frequent expression of interleukin-10 by Epstein-Barr Virus-harboring tumor cells of Hodgkin's disease. Blood. 1996; 87(7): 2918-2929. (Pubitemid 26102243)
30. Jucker M, Abts H, Li W, et al. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood. 1991, 77(11): 2413-2418.
31. Foss HD, Herbst H, Oelman E, et al. Lymhpotoxin, tumor necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. Br) Haematol. 1993; 84(4): 627-635.
32. Duckers DF, Jaspars LH, Voss W, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and negative cases of Hodgkin's disease. J Pathol. 2000; 190(2): 143-149. (Pubitemid 30082486)
33. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993; 54: 1-78. (Pubitemid 23289250)
34. Barton BE. The biological effects of interleukin 6. Med Res Rev. 1996; 16(1): 87-109. (Pubitemid 26034189)
35. Herbst H, Samol J, Foss HD, Raff T, Niedobitek G. Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol. 1997; 182(3): 299-306. (Pubitemid 27285782)
36. Levy Y, Brauet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Investig. 1994; 93(1): 424-428. (Pubitemid 24030864)
37. Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels: clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol. 2000; 79(3): 110-113. (Pubitemid 30195606)
38. Viviani S, Notti P, Bonfante V, Verderio P, Valagussa P, Bonddonna G. Elevated pretreatment serum of IL-10 are associated with poor prognosis in Hodgkin's disease, the Milan Cancer Institute experience. Med Oncol. 2000; 17(1): 59-63. (Pubitemid 30159169)
39. Rautert R, Schinkothe T, Franklin J, et al. Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma. 2008; 49(11): 2091-2098.
40. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Reed-Sternberg cells.; Exp Med. 1999, 189(12): 1939-1946.
41. Ohshima K, Akaiwa M, Umeshita R, Suzumiya), Izuhara K, Kikuchi M. lnterleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology. 2001; 38(4): 368-375. (Pubitemid 34225031)
42. Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001; 97(1): 250-255. (Pubitemid 32061267)
43. Casasnovas RO, Mounier N, Brice P, et al. Plasma Cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Graupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007; 25(13): 1732-1740. (Pubitemid 46797954)
44. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989; 7(11): 1630-1636. (Pubitemid 19272832)
45. de Oliveira DE, Bacchi MM, Macarenco RS, Tagliarini JV, Cordeiro RC, Bacchi CE. Human papillomavirus and Epstein-Barr virus infection, p53 expression, and cellular proliferation in laryngeal carcinoma. Am J Clin Pathol. 2006; 126(2): 284-293. (Pubitemid 44162576)
46. Enblad G, Molin D, Glimelius I, Fisher M, Nilsson G. The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2007; 21(5): 805-823. (Pubitemid 47487492)
47. Jones AS. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005; 175(6): 3463-3468.
48. Rose-John S, Serieller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006; 80(2): 227-236. (Pubitemid 44835496)
49. Gause A, Scholz R, Klein S, et al. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hematol Oncol. 1991; 9(6): 307-313.
50. Barton BE, Murphy TF. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine. 2001; 16(6): 251-257. (Pubitemid 34252608)
51. Barton BE. IL-6: insights into novel biological activities. Clin Immunol lmmunopathol. 1997; 85(1): 16-20.
52. Fiumara P, Cabanillas F, Younes A. Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. Blood. 2001; 98(9): 2877-2878.